ARDS: challenges in patient care and frontiers in research
Open Access
- 24 January 2018
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 27 (147) , 170107
Abstract
This review discusses the clinical challenges associated with ventilatory support and pharmacological interventions in patients with acute respiratory distress syndrome (ARDS). In addition, it discusses current scientific challenges facing researchers when planning and performing trials of ventilatory support or pharmacological interventions in these patients.Noninvasive mechanical ventilation is used in some patients with ARDS. When intubated and mechanically ventilated, ARDS patients should be ventilated with low tidal volumes. A plateau pressure 2O is recommended in all patients. It is suggested that a plateau pressure 2O should be considered safe. Patient with moderate and severe ARDS should receive higher levels of positive end-expiratory pressure (PEEP). Rescue therapies include prone position and neuromuscular blocking agents. Extracorporeal support for decapneisation and oxygenation should only be considered when lung-protective ventilation is no longer possible, or in cases of refractory hypoxaemia, respectively. Tracheotomy is only recommended when prolonged mechanical ventilation is expected.Of all tested pharmacological interventions for ARDS, only treatment with steroids is considered to have benefit.Proper identification of phenotypes, known to respond differently to specific interventions, is increasingly considered important for clinical trials of interventions for ARDS. Such phenotypes could be defined based on clinical parameters, such as the arterial oxygen tension/inspiratory oxygen fraction ratio, but biological marker profiles could be more promising.Keywords
This publication has 70 references indexed in Scilit:
- Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trialsAnnals of Intensive Care, 2012
- A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury*Critical Care Medicine, 2012
- Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trialThe Lancet, 2012
- Inflammation and matrix remodeling during repair of ventilator-induced lung injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Neuromuscular Blockers in Early Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2010
- Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trialThe Lancet, 2009
- Animal models of acute lung injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Comparison of Two Fluid-Management Strategies in Acute Lung InjuryNew England Journal of Medicine, 2006
- Higher versus Lower Positive End-Expiratory Pressures in Patients with the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2004
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000